How abnormal eye blood vessel types affect recovery after gas treatment for macular bleeding
Compares vision recovery across blood vessel types in people with age-related macular degeneration.
Plain-language title generated from the registry record
Registry title: Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages
Key facts
- Where
- Trento, ItalySee the site
Where in Italy
- Ospedale Santa Chiara di TrentoTrento, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Marco Mazzola
- Trial code
- NCT07427160
- Record updated
- 23 February 2026
- Original description
This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.Read full original descriptionShow less
Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages
This study investigates the prognostic value of macular neovascularization (MNV) subtypes in patients treated with pneumatic displacement for submacular hemorrhage. The researchers will compare anatomical and functional outcomes (visual acuity) between PCV, RAP, and other MNV forms within a Caucasian cohort to identify subtype-specific predictors of recovery.
Inclusion: Patients undergoing pneumatic displacement (PD) for submacular hemorrhage (SMH), secondary to macular neovascularization (MNV); Age 50 years or older at the time of SMH diagnosis; Caucasian ethnicity; SMH involving the central or internal ring of the Early Treatment Diabetic Retinopathy Study (ETDRS) grid (within a 3 mm circumference centered on the fovea); SMH dimensions equal to or greater than one papillary diameter; Pneumatic displacement treatment performed within 36 hours of SMH diagnosis.
Exclusion: Previous pneumatic displacement procedures for SMH in the study eye; Ocular surgery in the 8 weeks preceding the pneumatic displacement intervention; SMH secondary to conditions other than MNV; SMH estimated to be present for more than 15 days at the time of diagnosis; Presence of proliferative diabetic retinopathy in the study eye; Aphakia in the study eye; Inadequate pupillary dilation, media opacities, or other impediments to retinal imaging; Follow-up duration of less than 6 months following the procedure.